Latest Boardroom Shifts News

Aristocrat Leisure reported robust FY25 results with revenue up 11% to $6.3 billion and a 12% rise in normalised net profit after tax before amortisation. The company boosted dividends by 19% and completed key acquisitions and divestitures, positioning itself for future growth.

Flight Centre Travel Group reported a profit shortfall in FY25 but remains optimistic for FY26, driven by strategic investments, AI integration, and a diversified global portfolio.

Pro-Pac Packaging has entered voluntary administration, leading to the redundancy of its CEO and an extended timeline for creditor meetings in Australia and New Zealand.

Monash IVF Group has appointed Dr Victoria Atkinson as its new Managing Director and CEO, effective May 2026, signaling a strategic leadership shift for the assisted reproductive services provider.

Australian Critical Minerals has appointed geologist Allister Caird as a Non-Executive Director, alongside key leadership shifts including Dean DeLargie's move to Executive Chairman. These changes underscore the company’s strategic push in critical minerals exploration across Australia and Peru.

Megaport Limited has announced a fully underwritten A$200 million equity raising to fund its acquisition of Latitude.sh, a global Compute-as-a-Service platform, alongside a strategic investment to accelerate network expansion in India. The acquisition is expected to significantly enhance Megaport’s revenue and EBITDA on a pro forma basis for FY25.

Life360, Inc. reported robust Q3 2025 financial results driven by subscription and partnership revenue growth, alongside a leadership transition and strategic capital moves. The company also announced a major acquisition to bolster its advertising platform.

Tolu Minerals has appointed Dr Chris Muller as Managing Director and CEO, signaling a strategic push towards ramped-up exploration and resource development in Papua New Guinea.

Invex Therapeutics Ltd has had its trading suspension lifted following an announcement of new board and officer appointments, signaling a fresh chapter for the biotech company.

Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.

Integral Diagnostics has appointed Jason Martinez as its new CEO, set to lead the company’s growth and innovation efforts starting in 2026. Martinez brings over two decades of diagnostic imaging leadership experience, promising a strategic focus on expansion and operational excellence.

Iress launches a comprehensive FY26 business efficiency program targeting a 25% cash EBITDA margin, while narrowing its FY25 guidance and welcoming a new CEO.